Multiplex Assay Kit for Chitinase-3-like Protein 1 (CHI3L1) ,etc. by FLIA (Flow Luminescence Immunoassay)

GP39; CHI3-L1; YKL40; Chondrex; Chitinase 3-Like 1; Chondrocyte Protein YKL40; 39 kDa synovial protein

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Chitinase-3-like Protein 1 (CHI3L1) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Chitinase-3-like Protein 1 (CHI3L1) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Chitinase-3-like Protein 1 (CHI3L1) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Chitinase-3-like Protein 1 (CHI3L1) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 90-104 99
EDTA plasma(n=5) 87-101 92
heparin plasma(n=5) 78-96 85

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Chitinase-3-like Protein 1 (CHI3L1) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Chitinase-3-like Protein 1 (CHI3L1) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Chitinase-3-like Protein 1 (CHI3L1) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 99-105% 78-105% 86-95% 93-101%
EDTA plasma(n=5) 90-105% 90-99% 99-105% 95-105%
heparin plasma(n=5) 86-101% 80-102% 96-105% 79-103%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:CHI3L1) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Molecular and Cellular Biochemistry Serum YKL-40: a potential biomarker for psoriasis or endothelial dysfunction in psoriasis? Pubmed:25421412
BMC Pulmonary Medicine YKL-40 is correlated with FEV1 and the asthma control test (ACT) in asthmatic patients: influence of treatment Pubmed:25578181
International Journal of Rheumatic Diseases Assessment of pulsed electromagnetic field therapy with Serum YKL‐40 and ultrasonography in patients with knee osteoarthritis PubMed: 25955771
Respiratory Research YKL-40 expression in chronic obstructive pulmonary disease: relation to acute exacerbations and airway remodeling Pubmed:27013031
United States Patent Application Compositions and Methods for Diagnosing Lung Cancer y2016:0077095.html
Chronic obstructive pulmonary disease (COPD)--from biomarkers to clinical phenotypes ISBN:978-951-51-4039-5
EYE YKL-40 is a local marker for inflammation in patients with pseudoexfoliation syndrome Pubmed: 30560917
European Review for Medical and Pharmacological Sciences Astrocytes induce proliferation of oligodendrocyte progenitor cells via connexin 47-mediated activation of Chi3l1 expression Pubmed: 31002152
International journal of molecular sciences Differences in Osteoimmunological Biomarkers Predictive of Psoriatic Arthritis among a Large Italian Cohort of Psoriatic Patients Pubmed: 31717649
Research square Oligodendrocyte Progenitor Cells Increase Chi3l1 Secretion in Exosome to Activate Myh9 and Promote Proliferation through Connexin47 Connected to …
International Journal of Chronic Obstructive Pulmonary Disease High Blood Eosinophil and YKL-40 Levels, as Well as Low CXCL9 Levels, are Associated with Increased Readmission in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease 33814903
Catalog No. Related products for research use of Rattus norvegicus (Rat) Organism species Applications (RESEARCH USE ONLY!)
APB463Ra01 Active Chitinase-3-like Protein 1 (CHI3L1) Cell culture; Activity Assays.
RPB463Ra01 Recombinant Chitinase-3-like Protein 1 (CHI3L1) Positive Control; Immunogen; SDS-PAGE; WB.
PAB463Ra01 Polyclonal Antibody to Chitinase-3-like Protein 1 (CHI3L1) WB; IHC; ICC; IP.
MAB463Ra21 Monoclonal Antibody to Chitinase-3-like Protein 1 (CHI3L1) WB; IHC; ICC; IP.
SEB463Ra ELISA Kit for Chitinase-3-like Protein 1 (CHI3L1) Enzyme-linked immunosorbent assay for Antigen Detection.
LMB463Ra Multiplex Assay Kit for Chitinase-3-like Protein 1 (CHI3L1) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.